OMCL: Comparative study of the clinical efficacy of pegylated interferon α-2a and pegylated interferon α-2b in the treatment of e-antigen-positive hepatitis B and improvement of inflammatory factors and hemodynamics

Background: Chronic hepatitis B (CHB) is one of the most prevalent infectious diseases worldwide, caused by the hepatitis B virus (HBV), which is highly
contagious.

At present, the treatment of chronic hepatitis B mainly relies on conservative treatment, mainly through antiviral, immunomodulatory, anti-inflammatory, hepatoprotective and other methods to inhibit or eliminate hepatitis B virus infection
for a long time.

At present, commonly used in clinical practice, peginterferon α-2a and pegygin α-2b, the efficacy of these two interferons on chronic hepatitis B is well documented
.

In addition, we found that most previous studies on the treatment of chronic hepatitis B by peginterferon α-2a and peginterferon α-2b focused on the patient's hepatitis virus infection and ignored other
vital signs.

Objective: With the increasing incidence of chronic viral hepatitis B and its main threats, it is necessary to find appropriate treatment as soon as possible
.

MethodsThe clinical data of 84 patients with chronic viral hepatitis B admitted to the Second Hospital of Shanxi Medical University from January 2018 to January 2019 were retrospectively analyzed, and divided into two groups: group 2a was treated with pegyginterferon α-2a, and group 2b was treated
with pegyginterferon α-2b 。 Liver function (ALT, AST, HA, LN, IV-C), HEPATITIS B virus deoxyribonucleic acid (HBVdna), hepatitis B surface antigen (HBs), hepatitis B e antigen (HBeAg) and inflammatory factors (IFs, IL-1β, IL-6, IL-8, tumor necrosis factor-α) were tested at 12 weeks (T1), 24 (T2), and 48 (T3),
respectively.

Results: The total effective rates were similar for both groups (P>0:05
).

Table 1 Clinical efficacy [n%].

Figure 1: Comparison
of liver function.

Figure 2: Comparison
of tag transformations.

Table 2 Comparison of tag conversions [n \u% 3
].

Figure 3 Prognostic comparison
.

Conclusion: Interferon peg(PEG) α-2a and interferon pegylate α-2b have good and stable therapeutic effect on HBe Ag-positive chronic hepatitis B, of which peginterferon α-2b treatment process is faster, but the side effects are large, which can provide valuable reference
for clinical choice of treatment plan.

Original source:

Jia N, Gao W, Fan X,et al.